DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly valued, ...
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the ...
The company will unveil Dexcom Smart Basal*, a new integrated titration module designed to make basal insulin initiation and management easier† for users, which is currently under FDA and CE mark ...
Medicare Part B typically covers continuous glucose monitors (CGMs) like the Dexcom G7, as they are Food and Drug Administration (FDA)-approved durable medical equipment items. To get a Dexcom G7 CGM ...
VIENNA--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in glucose biosensing, will present new product features and a compilation of new evidence that shows the benefits of its glucose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results